Pyxis Oncology, Inc.
NASDAQ:PYXSBiotechnology
+$0.11 today
- Market cap
- $168.65M
- Beta
- 1.43
- P/E (TTM)
- -1.6
- EPS (TTM)
- -$1.29
Volume 0.75M
Average 0.50M
PYXS EBITDA
Earnings before interest, taxes, depreciation, and amortization; a proxy for operating profit before non-cash and financing charges.
Pyxis Oncology, Inc.NASDAQ: PYXS
EBITDA · Q1 FY2026 · quarter ended Mar 2026
EBITDA remains negative
Q1 FY2026 EBITDA was -$22.81M, compared with -$20.61M a year earlier. Trailing-twelve-month EBITDA was -$75.93M.
Context
- EBITDA amounted to 532.0% of revenue in FY2025, up 126.2 pp from a year earlier.
- EBITDA grew in size in 1 of the last 3 fiscal years.
What to watch
Whether EBITDA reaches the consensus estimate from 9 analysts of -$67.62M (+8.3%) for the fiscal year ending Dec 2026, a step up from the -12.5% reported in FY2025.
Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterMar 2026
- -$22.81M-61.6% QoQ
- Last fiscal yearDec 2025
- -$73.72M-12.5% YoY
- LTMMar 2026
- -$75.93M+0.5% YoY
| Horizon | Past | Forecast | Difference |
|---|---|---|---|
| Quarter | -10.7% | -65.0% | -54.2 pp |
| 1 year | -12.5% | +8.3% | +20.8 pp |
| 3-year CAGR | — | — | — |
| 5-year CAGR | — | — | |
| 10-year CAGR | — | — |
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
EBITDA history
USD · from the income statement
- Latest · FY2025
- (73.72M) USD
- Year-over-year change
- -12.5%
| Period | Period end | EBITDA | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | (73.72M) | -12.5% |
| FY2024 | 2024-12-31 | (65.51M) | +8.8% |
| FY2023 | 2023-12-31 | (71.86M) | +40.1% |
| FY2022 | 2022-12-31 | (120.01M) | -59.3% |
| FY2021 | 2021-12-31 | (75.33M) | — |
EBITDA vs competitors
How PYXS compares with its peers on the latest reported figures
- PYXS's LTM Mar 2026 EBITDA of -$75.93M is the 6th highest of the 10 companies compared; the peer median is -$75.47M.
- Its year-over-year change of +0.5% is the 6th highest of 10, against a peer median of +7.0%.
- EBITDA amounts to 547.9% of revenue for PYXS, versus a peer median of 653.9%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | -$46.56M | +46.6% | — | 67.3% | |
| LTM Mar 2026 | -$58.85M | +7.0% | — | — | |
| LTM Mar 2026 | -$72.53M | +7.7% | — | 257.0% | |
ZURAZura Bio Limited | LTM Mar 2026 | -$75.38M | -21.4% | — | — |
| LTM Mar 2026 | -$75.47M | +22.0% | — | 33540.9% | |
| LTM Mar 2026 | -$75.93M | +0.5% | — | 547.9% | |
| LTM Mar 2026 | -$79.77M | -33.1% | — | 3956.7% | |
| LTM Mar 2026 | -$111.97M | +23.4% | — | 999.5% | |
| LTM Mar 2026 | -$112.54M | -37.5% | — | 308.4% | |
| LTM Mar 2026 | -$179.89M | -30.1% | — | — | |
| Peer median (excluding PYXS) | -$75.47M | +7.0% | — | 653.9% | |
Competitors are the stored peer set for PYXS. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 16.15M | 13.86M |
| Cost of Revenue | 0 | 0 | 0 | 475K | 2.39M |
| Gross Profit | 0 | 0 | 0 | 15.67M | 11.47M |
| Gross Margin | — | — | — | 97.1% | 82.8% |
| Research & Development | 51.05M | 86.13M | 49.59M | 58.75M | 73.7M |
| Selling, General & Admin | 18.66M | 37.35M | 32.61M | 25.42M | 22.19M |
| Operating Expenses | 69.72M | 123.48M | 82.2M | 105.13M | 95.89M |
| Depreciation & Amortization | 647K | 709K | 1.93M | 2.98M | 4.51M |
| EBITDA | (75.33M) | (120.01M) | (71.86M) | (65.51M) | (73.72M) |
| EBITDA Margin | — | — | — | -405.8% | -532.0% |
| Operating Income | (69.72M) | (123.48M) | (82.2M) | (89.46M) | (84.42M) |
| Operating Margin | — | — | — | -554.1% | -609.2% |
| Interest Income | 23K | 2.76M | 6.63M | 7.04M | 3.61M |
| Interest Expense | 0 | 0 | 0 | 0 | 0 |
| Other Income / Expenses | (6.26M) | 2.76M | 8.41M | 9.97M | 6.19M |
| Income Before Tax | (75.98M) | (120.72M) | (73.79M) | (79.5M) | (78.24M) |
| Pre-Tax Margin | — | — | — | -492.4% | -564.5% |
| Income Tax Expense | 0 | 0 | 0 | (2.16M) | 1.39M |
| Net Income | (75.98M) | (120.72M) | (73.79M) | (77.33M) | (79.62M) |
| Net Margin | — | — | — | -478.9% | -574.5% |
| EPS (Basic) | (2.53) | (3.57) | (1.85) | (1.32) | (1.28) |
| EPS (Diluted) | (2.53) | (3.57) | (1.85) | (1.32) | (1.28) |
| Weighted Avg Shares | 32.22M | 33.03M | 39.9M | 58.45M | 62.14M |
| Weighted Avg Shares (Diluted) | 32.22M | 33.03M | 39.9M | 58.45M | 62.14M |
Pyxis Oncology, Inc.
NASDAQ:PYXS
Intrinsic Alpha fair value
Locked
Current Price
$1.41
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.